Aptar Digital Health acquires Healint to enhance portfolio and drive growth

Aptar Digital Health, a global leader in digital health solutions, has acquired Healint, a digital health company known for its virtual clinical studies, real-world evidence platform, and mobile apps supporting patients with neurological and immunological conditions. The acquisition aligns with Aptar Digital Health's strategy to expand its portfolio in neurology and enhance its global presence in digital health. The added capabilities include patient community management, AI-based data collection and analysis, digital diagnostics, and accelerated global clinical studies. Healint's expertise in multimodal health tracking and real-world evidence generation, particularly through its Migraine Buddy app, complements Aptar Digital Health's holistic ecosystem of digital interventions.

The integration of Healint into Aptar Digital Health aims to provide additional value to pharmaceutical customers by offering a comprehensive solution throughout the drug lifecycle. Healint's AI-powered precision medicine Software as a Medical Device (SaMD) will be developed to augment existing treatments using unique datasets and scientific expertise. Aptar Digital Health plans to scale up Healint's platform to address adjacent therapeutic indications in neurology and immunology, expanding its services and strengthening its current offerings, including clinical trial management tools.

The acquisition reflects Aptar Digital Health's commitment to improving patient experiences and health outcomes by combining the expertise of both companies in developing state-of-the-art solutions for patient empowerment in their disease journey.